Can MRNS go the distance this week?"On Tuesday, the company earned attention from analysts at H.C. Wainwright. The research firm initiated coverage on MRNS stock. It gave the company a “BUY” rating as well as a price target of $5 per share. This was the 3rd analyst firm to initiate coverage on the stock this year. Previous to H.C. Wainwright, Jefferies and Leerink Swann both initiated coverage with “BUY” and “Outperform” ratings, respectively, for the penny stock. The two other firms also..."
3 Penny Stocks Making New Highs In September
NASDAQ:MRNS
Biotech
ABEO Stock To Watch (But For How Long?)ABEO stock has been beaten down for much of 2019. It had declined by as much as 80% since the beginning of the year. It went on to emerge as one of the biggest gainers in the market yesterday. The company announced that it was going to explore options that could unlock value for the shareholders. It stated that even an outright sale or a takeover is being considered. However, volume has been cut down dramatically on Wednesday compared to Tuesday's volume. How long can the run sustain and what will come of ABEO later this month?
3 Penny Stocks Making New Highs In September
NASDAQ:ABEO
BEARISH HARMONIC GARTLEY ADMA FAILED TO BREAK RESISTANCE. THIS ALSO HAPPENS TO BE A BEARISH HARMONIC GARTLEY PATTERN WITH DECLINING STOCHASTIC, RSI AND VOLUME AT THE END OF A KEY FIBONACCI CYCLE.
PREVIOUS REPEATING STAIRWAY PATTERN SUGGEST'S PULLBACK COMING (SYMMETRICAL) . LOOK FOR APPROXIMATELY 618 RETRACEMENT FROM RECENT TOP (RESISTANCE).
DISCLOSURE : I AM LONG ADMA, I MAY BUY/ SELL WITHIN NEXT 72 HOURS. I AM NOT A FINANCIAL ADVISER AND THIS IS NOT A NOTE TO BUY OR SELL.
NTEC Jumped above $0.70 since falling apartWhat are the thoughts here? News? -NOPE...pure momentum today? Biggest volume it's had since the big drop day so what can explain this move?
"Intec Pharma Ltd. is a biotechnology company that creates drugs using its Accordion Pill technology. This technology is designed to improve the safety of drugs when taken orally. The company currently has 5 treatments in its pipeline with AP-CD/LD in Phase 3 trials.Over the last 2 trading sessions, Intec’s stock price has seen significant gains. On August 27th the stock price rose 14.8% and in premarket trading, on the 28th it has risen another 15%. These percentage gains allowed the biotech penny stock to go from $0.45 to $0.61."
Original Article: 4 Penny Stocks To Watch Under $4
NASDAQ:NTEC
Autonomous AI Robotic Trading Decimates Mallinckrodt Share PriceMallinckrodt named the best biotech stocks to sell short in a decade
Repeating Pattern #VolatilityWatchNeckline (outlined in blue) for inverse Head and shoulders.
Harmonic Cypher pattern @786 retracement, where ADMA bounced.
RSI moving up with trend, showing strong accumulation (Bulls in control)
Highlighted in the blue box's is a pattern that I've been watching for awhile now. As you can see, they are very similar and just so happens that today's close was pushing up against the top of the neckline for the head and shoulders.
Seems ADMA could have a significant move within the next few days
Also, for those who aren't familiar with ADMA, they do have an announcement/PR for one of their lead products - Bivigam, to launch... Coming soon =)
Please like and follow so I can continue finding awesome charts. Thank you in advance everyone d=)
Disclosure: I am long ADMA. This is not a note to buy or sell, please do your homework before investing.
$AMPE Ampio Pharmaceuticals Inc A Good Risk/Reward PlayWe are really liking the chart on $AMPE. You have the rounding bottom and there looks to be accumulation going on.
Currently trading at $.62 a share, the 52-week low is $.35 a share.
We believe $AMPE has breakout written all over it and there is an upcoming catalyst that can send the stock flying higher. The company is due to hear from the FDA shortly. Here's what the company said last month in its update:
Ampio Pharmaceuticals has been in contact with the U.S. Food and Drug Administration (FDA) regarding the Special Protocol Assessment (SPA) following its re-submission of a revised protocol for AP-013, which the Company believes implements all of the Agency's recommendations provided since the beginning of the SPA review cycle. The Agency confirmed that it would make every effort to expedite this review, however due to a heavy workload, they were not able to commit to providing a response to the Company's SPA re-submission earlier than the 45-day window outlined in the Guidance for Industry Special Protocol Assessment, leading the Company to expect the response will be in mid-June rather than late May 2019, as previously predicted.
There is some debate on social channels as to when this news will hit the tape. Some are saying any day now, while others are saying after the July 4th holiday.
As always, trade with caution and use protective stops.
Good luck to all!
$VIVE Viveve Medical Inc Has Gaps To Fill$VIVE has come across our screen after the company received 510k approval of its Viveve System 2.0, which is its second generation product. This is a big development and explains why the stock is up 24% today.
We believe there's a lot more room for $VIVE to run as there are gaps above that need to be filled. There's $1.50 to $1.84 and then $2.50 to $3.18
Furthermore, the risk/reward looks good. Can go Long here with a stop at new 52-week lows at $.41 a share.
As always, trade with caution and use protective stops.
Good luck to all!
About Viveve
Viveve Medical, Inc. is a medical technology company focused on women's intimate health. Viveve is committed to advancing new solutions to improve women's overall well-being and quality of life. The internationally patented Viveve® System incorporates cryogen-cooled monopolar radiofrequency (CMRF) technology to uniformly deliver volumetric heating while gently cooling surface tissue to generate neocollagenesis in a single in-office session.
International regulatory approvals and clearances have been received for vaginal laxity and/or improvement in sexual function indications in over 50 countries. Viveve is conducting VIVEVE II, a multicenter, randomized, double-blind, sham-controlled clinical trial to assess improvement of sexual function in women following vaginal childbirth. Completion of full 250 subject enrollment was announced in early March 2019. If successful, VIVEVE II results could support a marketing application for a new U.S. commercial indication. Currently, in the United States, the Viveve® System is cleared by the FDA for use in general surgical procedures for electrocoagulation and hemostasis.
Viveve has fully enrolled LIBERATE-International, one of two planned independent, multicenter, randomized registration trials for the improvement of stress urinary incontinence in women and plans to re-submit an IDE to the FDA for LIBERATE-U.S. after conducting certain safety testing. The results of these two trials, if successful, could support marketing applications in the U.S. and over 30 countries around the world for this new commercial indication.
Deja Vu?Almost exactly one-year ago NDRA received this same form 8-K "Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing." *Shortly after recieving this notice, NDRA's Price shot up dramatically.
In September, ENDRA Life Sciences is planning to present the final results of the #Robarts study in conjunction with the upcoming EASL-NAFLD Summit in Seville, Spain.
Pattern is very similar to last year's notification.
Disclosure: I am long NDRA. This is not a note to buy or sell. Please do your own Homework before investing.
(Nasdaq: CODX) Bullish signal - GOLDEN CROSSThis could be the next NASDAQ Biotech ready to move in a big way, here's why...
(Nasdaq: CODX) displaying the Holy grail of Bullish signals - a GOLDEN CROSS.
The 50 Day EMA just crossed the 200 Day EMA, which most of you know by now is a bullish signal that indicates a potential breakout is on the Horizon.
Here Is Another Potential "Breakout Catalyst" In Play
Wall Street Analysts at H.C. Wainwright & Maxim Group have both given Co-Diagnostics (Nasdaq: CODX) Buy rating with a $2.00 Price Target, almost double its price at Fridays close, suggesting the stock has a potential upside of +80%.
Photocure $PHO.OL stock pullback after Q2 is chance to buyPhotocure $PHO.OL OSL:PHO presented Q2 2019 numbers today, with most numbers landing very close to expectations.
Webcast: webtv.hegnar.no
Press release: newsweb.oslobors.no
Armchair Healthcare podcast interview with CEO Dan Schneider: twitter.com
Bearish Butterfly SGEN has beat biotech averages significantly the past few months and has come to meet my $80 pt which also happens to make a bearish harmonic butterfly pattern. This could have a little more upside as it tests $80-81 but risk/reward would suggest a potential double top that can take this down quite a bit in a short amount of time. If I was short I would be looking to start a position.
According to the bearish setup SGEN should find 50 -618 retracement before next ER bringing SGEN down to around the $69 mark. As I have outlined in this setup, SGEN is still making higher lows on long-term chart and after retracing back to $69, should see continue uptrend to ~$84 (assuming another positive ER or catalyst).
Tip - Even if you rely mostly on company fundamentals, you should be aware of support/ resistance levels.
Please Follow, like, comment, and share so I can continue finding awesome trades. Thank you in advance >+)
Find me on Twitter or Instagram @VolatilityWatch
Disclosure: I do not own a position in SGEN. I may buy/sell within the next 72 hours. This is not a note to buy or sell, please do your homework before investing.
G1 Therapeutics RALLYEarnings/News
Co's lead cancer therapy, trilaciclib, gets FDA's "breakthrough therapy" status, which is meant to speed up review of drugs that treat life-threatening conditions
GTHX says it will present new data on three of its drugs, including trilaciclib, at an upcoming conference in September
FDA's move is a recognition that clinical data presented so far reflects the potential for trilaciclib to address an urgent unmet medical need - Cowen & Co
Analyst Actions
JP Morgan Upgrades G1 Therapeutics to Overweight From Neutral, PT Raised to $45 From $38